Apexus secures HRSA contract, continues to serve as prime vendor of 340B Drug Pricing Program

Apexus, LLC, the prime vendor for the 340B Drug Pricing Program, has announced that it has been selected by the Health Resources and Services Administration (HRSA) to continue serving in its role as the prime vendor through September 29, 2019. Apexus, which has held this position for the past 10 years, will continue to work with more than 25,000 safety-net provider locations, drug manufacturers, pharmacy wholesalers, and other stakeholders to negotiate discounts on pharmaceuticals and offer valued services, while supporting compliant operations and helping stakeholders to continue to deliver health care services to underserved populations.

"We are thrilled and proud for the opportunity to continue working with HRSA to strengthen this important program that helps so many families across the nation gain access to essential medications," said Apexus President Chris Hatwig. "With our team's unsurpassed knowledge of the 340B Program, our unique national distribution channels, and our highly regarded educational programs, we are able to deliver maximum value to 340B stakeholders through the promotion of program integrity, compliance, and optimization of the program."